NASDAQ:XENE
Xenon Pharmaceuticals Inc. Stock News
$42.49
+1.84 (+4.53%)
At Close: May 01, 2024
Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update
09:01pm, Tuesday, 01'st Mar 2022 GlobeNewswire Inc.
Conference Call at 4:30 pm ET Today Conference Call at 4:30 pm ET Today
Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update
09:01pm, Tuesday, 01'st Mar 2022 GlobeNewswire
Conference Call at 4:30 pm ET Today Conference Call at 4:30 pm ET Today
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates
07:10pm, Tuesday, 01'st Mar 2022
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -21.28% and 11.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto
Tabula Rasa Healthcare (TRHC) Reports Q4 Loss, Tops Revenue Estimates
01:10am, Friday, 25'th Feb 2022 Zacks Investment Research
Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of -28.57% and 0.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate Update
09:01pm, Tuesday, 22'nd Feb 2022 GlobeNewswire Inc.
BURNABY, British Columbia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its financial res
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate Update
04:01pm, Tuesday, 22'nd Feb 2022
BURNABY, British Columbia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its financial resul
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
01:15pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
09:01pm, Monday, 14'th Feb 2022 GlobeNewswire Inc.
BURNABY, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one
Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
04:01pm, Monday, 14'th Feb 2022
BURNABY, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one in
Xenon draws buyout speculation after Zogenix deal
03:51pm, Wednesday, 19'th Jan 2022 Seeking Alpha
Dealreporter flags Xenon Pharmaceuticals <> as a potential acquisition target following the agreement between Zogenix <> and UCB under which the Belgian drugmaker offered
Xenon passes regulatory mark to receive $15M from Neurocrine Biosciences
01:22pm, Wednesday, 12'th Jan 2022 Seeking Alpha
Xenon Pharmaceuticals (XENE) reaches regulatory milestone to receive a payment of $15M from Neurocrine Biosciences (NBIX) under its collaboration to develop treatments for epilepsy. It
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
01:00pm, Wednesday, 12'th Jan 2022 GlobeNewswire Inc.
BURNABY, British Columbia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develo
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022
01:30pm, Monday, 10'th Jan 2022 GlobeNewswire Inc.
BURNABY, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestones for 2022.
Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech
07:30pm, Wednesday, 29'th Dec 2021 Benzinga
For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chico said Wednesday on "PreMarket Prep Plus."
Chico, the senior
Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech
02:30pm, Wednesday, 29'th Dec 2021
For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chico said Wednesday on "PreMarket Prep Plus." Chico, the senior
